Key Points
- Insider sale: EVP Craig Hopkinson sold 9,000 shares on April 1 at an average price of $35.51 for $319,590, cutting his stake by 9.54% to 85,389 shares valued at about $3.03M.
- Q4 results and stock stats: Alkermes missed EPS estimates ($0.29 vs. $0.43) with revenue $384.6M (down 10.6% YoY); shares opened at $34.84, with a 12‑month range of $25.17–$36.48 and a market cap of $5.79B.
- Analyst and institutional view: The consensus rating is a "Moderate Buy" with an average price target of $43.93, and institutional investors own roughly 95.21% of the stock, with several large funds recently increasing positions.
Alkermes plc (NASDAQ:ALKS - Get Free Report) EVP Craig Hopkinson sold 9,000 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $35.51, for a total transaction of $319,590.00. Following the sale, the executive vice president directly owned 85,389 shares in the company, valued at approximately $3,032,163.39. This trade represents a 9.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Alkermes Stock Down 0.6%
Shares of Alkermes stock opened at $34.84 on Friday. Alkermes plc has a 12 month low of $25.17 and a 12 month high of $36.48. The stock has a market cap of $5.79 billion, a PE ratio of 24.36, a price-to-earnings-growth ratio of 8.74 and a beta of 0.44. The business has a fifty day simple moving average of $31.40 and a 200-day simple moving average of $30.31.
Alkermes (NASDAQ:ALKS - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.29 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.14). The business had revenue of $384.55 million for the quarter, compared to analyst estimates of $380.44 million. Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The company's revenue was down 10.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.05 earnings per share. Analysts expect that Alkermes plc will post 1.31 EPS for the current fiscal year.
Analysts Set New Price Targets
ALKS has been the subject of several recent research reports. HC Wainwright reissued a "neutral" rating and issued a $43.00 target price on shares of Alkermes in a research report on Thursday, February 26th. Wolfe Research started coverage on Alkermes in a research report on Monday, February 23rd. They issued an "outperform" rating and a $45.00 price target on the stock. Royal Bank Of Canada dropped their price objective on shares of Alkermes from $47.00 to $45.00 and set an "outperform" rating on the stock in a report on Thursday, February 26th. Weiss Ratings restated a "hold (c+)" rating on shares of Alkermes in a research note on Monday, December 29th. Finally, Wells Fargo & Company increased their price target on shares of Alkermes from $37.00 to $43.00 and gave the stock an "overweight" rating in a research report on Thursday, February 26th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $43.93.
Check Out Our Latest Stock Report on ALKS
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. Baker BROS. Advisors LP lifted its stake in shares of Alkermes by 23.7% during the fourth quarter. Baker BROS. Advisors LP now owns 10,012,267 shares of the company's stock valued at $280,143,000 after acquiring an additional 1,920,916 shares during the period. State Street Corp boosted its position in shares of Alkermes by 10.9% during the fourth quarter. State Street Corp now owns 9,472,858 shares of the company's stock worth $265,051,000 after purchasing an additional 932,507 shares in the last quarter. Renaissance Technologies LLC grew its stake in Alkermes by 6.0% in the fourth quarter. Renaissance Technologies LLC now owns 6,668,028 shares of the company's stock valued at $186,571,000 after acquiring an additional 375,500 shares during the period. JPMorgan Chase & Co. grew its position in shares of Alkermes by 32.0% in the 4th quarter. JPMorgan Chase & Co. now owns 5,184,547 shares of the company's stock valued at $145,064,000 after purchasing an additional 1,256,377 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Alkermes by 19.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,412,783 shares of the company's stock valued at $123,467,000 after buying an additional 714,787 shares during the period. Institutional investors and hedge funds own 95.21% of the company's stock.
Alkermes Company Profile
(
Get Free Report)
Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes' portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.
Alkermes' commercial franchise features several approved products.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
